The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Open accessAbstract
PURPOSE: SJMB03 (ClinicalTrials.gov identifier: NCT00085202 ) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma. PATIENTS AND METHODS: Patients 3-21 years old were stratified into average-risk and high-risk treatment groups based on metastatic status and extent of resection. Medulloblastomas were molecularly classified into subgroups (Wingless [WNT], Sonic Hedgehog [SHH], group 3, and group 4) and subtypes based on DNA methylation profiles and overlaid with gene mutations from next-generation sequencing. Coprimary study end points were (1) to assess the relationship between ERBB2 protein expression in tumors and progression-free survival (PFS), and (2) to estimate the frequency of mutations associated with WNT and SHH tumors. Clinical and molecular risk factors were evaluated, and the most robust were used to model new risk-classification categories. RESULTS: Three hundred thirty eligible patients with medulloblastoma were enrolled. Five-year PFS was 83.2% (95% CI, 78.4 to 88.2) for average-risk patients (n = 227) and 58.7% (95% CI, 49.8 to 69.1) for high-risk patients (n = 103). No association was found between ERBB2 status and PFS in the overall cohort ( P = .74) or when patients were stratified by clinical risk ( P = .71). Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors and PTCH1 (38%), TP53 (21%), and DDX3X (19%) in SHH tumors. Methylome profiling classified 53 WNT (17.4%), 48 SHH (15.7%), 65 group 3 (21.3%), and 139 group 4 (45.6%) tumors. A comprehensive clinicomolecular risk factor analysis identified three low-risk groups (WNT, low-risk SHH, and low-risk combined groups 3 and 4) with excellent (5-year PFS > 90%) and two very high-risk groups (high-risk SHH and high-risk combined groups 3 and 4) with poor survival (5-year PFS < 60%). CONCLUSION: These results establish a new risk stratification for future medulloblastoma trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“we developed the Medulloblastoma Meta-Analysis (MB-meta) portal, which integrates clinical, genomic, and survival data from 898 patients across three major medulloblastoma clinical trials (16–18).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chávez, L., Reuß, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,114
Self-citationMolecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
Self-citationMedulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S. C., Bouffet, É., Clifford, S. C., Hawkins, C. E., French, P. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,353
Self-citationIntertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
Self-citationThe whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112
Self-citationPacker, R. J., Gajjar, A. J., Vézina, G., Rorke-Adams, L. B., Burger, P. C., Robertson, P. L., Bayer, L. A., Lafond, D. A., Donahue, B. R., Marymont, M. H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4980 · Cited by 985
Self-citationGajjar, A. J., Chintagumpala, M., Ashley, D. M., Kellie, S. J., Kun, L. E., Merchant, T. E., Woo, S. Y., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citationSubgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Morrissy, A. S., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 887
Self-citationRausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Self-citationNovel mutations target distinct subgroups of medulloblastoma
Robinson, G. W., Parker, M. D., Kranenburg, T. A., Lu, C., Chen, X. '., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 853
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Gilbertson RJ, 1998, Cancer Res, 58, 3932
Cited by
Sorted by citations
Items 201–243 of 243
Musarra, M., Chen, J., Mitchell, L., Dunne, G., Maurice, L., Nguyen, L., Cahill, H., Hassan, S. P., Nelson, A., & Manoharan, N. (2025) · JCO oncology advances. · doi:10.1200/oa-25-00073
Huang, R., Lü, X., Sun, X., & Wu, H. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06327-2
Reduced versus standard dose craniospinal irradiation with chemotherapy to treat medulloblastoma
Hazzard, I., Georgies, M. M., Bali, M., Tabaie, E. A., & Frezza, E. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001366
Growth hormone replacement therapy does not predict relapse across medulloblastoma subgroups
Caballero, M., Wilhelmsson, M., Wasserman, J. D., McKeown, T., Tsang, D. S., Tabori, U. Y., Huang, A., Liu, A. P. Y., Das, A., Bennett, J., et al. (2025) · Neuro-Oncology Pediatrics · doi:10.1093/neuped/wuaf006
Self-citationGrowth hormone replacement therapy in medulloblastoma survivors: Editorial
Lodish, M. B., & Bailey, S. (2025) · Neuro-Oncology Pediatrics · doi:10.1093/neuped/wuaf010
Kasem, R. A., Huang, M. A., Beall, J., & Mistry, A. M. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf211
Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaPreprint
Liu, J., Xu, Y., Zhu, M., Dong, X., Zhou, H., Bianski, B. M., Jonchère, B., Lin, W., Fu, X., Bhatara, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.20.689490
Self-citationStrategic modulation to avoid radiation toxicities for brain integrity (SMART-BRAIN)
Kowalchuk, R. O., Fossati, P., Miller, J. M., Sorenson, K. L., Spears, G. M., Frechette, K. M., Kraling, A. J., Wilson, Z., Daniels, D. J., Schwartz, J., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111685
Self-citationEmbryonal tumor of the central nervous system based on a Danio rerio model
Selina, P. I., & Lunina, N. A. (2025) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.17116/molgen20254304268
Flegontov, A., Druy, A. E., Protsvetkina, A. V., Zaytseva, M., Гегелия, Н. В., Petrova, V., Сенченко, М. А., Tarakanova, A. V., Sanakoeva, A. V., Artyomov, A. V., et al. (2025) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/j.993
Göbel, C., Godbole, S., Schoof, M., Holdhof, D., Kresbach, C., Loose, C., Neumann, J., & Schüller, U. (2024) · Figshare · doi:10.6084/m9.figshare.26634882
Göbel, C., Godbole, S., Schoof, M., Holdhof, D., Kresbach, C., Loose, C., Neumann, J., & Schüller, U. (2024) · Figshare · doi:10.6084/m9.figshare.26634885
Fukuoka, K., Kurihara, J., Shofuda, T., Kagawa, N., Yamasaki, K., Ando, R., Ishida, J., Kanamori, M., Kawamura, A., Park, Y.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26619622
Long-term toxicities of chemoradiotherapy in children with standard-risk medulloblastoma
Flegontov, A., Druy, A. E., Protsvetkina, A. V., Gaynullina, D. R., Evdokimova, M. A., Ilyina, E. Y., Artyomov, A. V., Горностаев, В. В., Salnikova, Е. А., Sysoev, A. E., et al. (2026) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2025-12-4-37-55
Su, Y., Deng, K., Chen, X., Feng, Z., Wang, D., Daniels, C., Koh, H. Y., Gonzalez, R. D., Suzuki, H., Miyauchi, T., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01454-4
Go, K., Katsuma, A., Yoshioka, E., Shofuda, T., Fukuoka, K., Ichimura, K., Matsushita, Y., Mineharu, Y., Makino, Y., Kawauchi, T., et al. (2026) · Brain Pathology · doi:10.1111/bpa.70092
Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma
Abu-Arja, M. H., Stuckert, A. J., Ghebrelul, R. T., Chintagumpala, M., Taylor, M. D., & Ahmed, N. M. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05437-2
Self-citationThe future of targeted therapies for pediatric central nervous system tumors
Lindsay, H., & Bouffet, É. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf188
Agarwal, S., & Lazareff, J. A. (2026) · Surgical Neurology International · doi:10.25259/sni_1174_2025
Sonic Hedgehog signaling pathway: overview and treatment considerations in brain tumors
Rosenberg, T., Salloum, R., & Filbin, M. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00027-9
Chemotherapy for medulloblastoma—childhood
Szalontay, L., Kilburn, L. B., & Packer, R. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00057-7
Khan, S., Lazow, M., Tanaka, R., Fouladi, M., & Abu‐Arja, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00053-x
Medulloblastoma : Treatment Progress and Future Prospective
Yamaguchi, S., Ishi, Y., & Fujimura, M. (2025) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.34.195
Glass, J. O., Steffl, J., Patni, T., Liang, J., Li, Y., Ashford, J. M., Robinson, G. W., Gajjar, A. J., Conklin, H. M., Merchant, T. E., et al. (2026) · SPIE Medical Imaging: Clinical and Biomedical Imaging · doi:10.1117/12.3085890
Self-citationEmbryonal Tumor Models of the Central Nervous System Based on a Danio rerio
Selina, P. I., & Лунина, Н. А. (2025) · Molecular Genetics Microbiology and Virology · doi:10.3103/s089141682570034x
Wu, H., Wu, C., Lin, S.-C., Wu, C., Chen, H.-H., Chen, Y.-W., Lee, Y.-Y., Yang, C.-H., & Chang, F. (2026) · Neuroradiology · doi:10.1007/s00234-026-04003-x
Treatment deintensification in average-risk medulloblastoma: Less is more?
Hall, M. D., & Abdelbaki, M. S. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag118
Chun, S.-J., Kim, N., Lim, D. H., Kim, J.-Y., Wee, C. W., Yoon, H. I., Jeon, S. H., Kim, I. A., & Lee, J. H. (2026) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2026.101197
Wang, H. (2026) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.70211
Immune Cell Therapy Promises More Effective Cure for Medulloblastoma
Agostini, M., Traldi, P., & Hamdan, M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060326
Yang, P., Lin, H., Li, M. M., Lei, J., Richard, S. A., & Lan, Z. (2026) · Psycho-Oncology · doi:10.1002/pon.70528
Sabet, K., Lovell, H., & Fonseca, A. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07376-9
Fulminant extraneural metastases in MYC-amplified Group 3 medulloblastoma: a pediatric case report
Chen, L., Li, S., Wang, L., Li, H., Cai, L., & Lai, M. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07351-4
From developmental origins to relapse: molecular and therapeutic insights in medulloblastoma
Tourigny, N., da Silva, C. F., & Ramaswamy, V. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07368-9
Surgical resection in medulloblastoma: a crossroads in the molecular era
McAbee, J. H., Laird, D. G., Gajjar, A. J., Hersh, D. S., Shimony, N., Aquilina, K., & Klimo, P. D. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07355-0
Self-citationEpendymoma-like tumor with mesenchymal differentiation harboring ZFTA::NCOA2 fusion: a case report
Kumon, M., Joko, M., Ohba, S., Fujiwara, E., Tanaka, M., Yamada, S., Takeuchi, Y., Inoue, Y., Miyahira, A., Nobusawa, S., et al. (2026) · Brain Tumor Pathology · doi:10.1007/s10014-026-00547-1
Uemura, S., Demizu, Y., Kawamura, A., Kozaki, A., Saito, A., Ishida, T., Mori, T., Bessho, R., Park, S., Sulaiman, N. S., et al. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70419
Echavidre, W., Picco, V., & Montemagno, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1930948
Feng, Z., Su, Y., Yang, L., Deng, K., Wang, J., Zhang, J., Liu, F., Wang, D., Liang, Y., Wang, W., et al. (2026) · Cancer Innovation · doi:10.1002/cai2.70079
Haidar, C. E., Yang, W., Harris, R. D., Ostrenga, A. R., Pappo, A. S., Hawkins, D. S., Yang, J. J., Lupo, P. J., & Bernhardt, M. B. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag286
Sarkar, C., Al-Hussaini, M. A., Santosh, V., Suri, V. S., Park, S., Piao, Y., Tihan, T., Ng, H., Buckland, M. E., Jalali, R., et al. (2026) · Brain Pathology · doi:10.1111/bpa.70136
Ertekin, M., Temuroglu, A., Aksoy, G. R., Taskapilioglu, M. O., & Sevinir, B. B. (2026) · Child s Nervous System · doi:10.1007/s00381-026-07496-2
The 2025 KSPNO Guideline for the Diagnosis and Treatment of Medulloblastoma
Kim, N., Cho, J., Jung, T., Park, S., Nam, S. J., Cha, Y. J., Lee, Y. S., Kim, Y., Lim, D. H., Yoon, H. I., et al. (2026) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2026.0027
Metadata
- Authors
- Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., Schechter, T., Hassall, T., Robertson, T., Nicholls, W., Gururangan, S., Schroeder, K., Sullivan, M., Wheeler, G., Hansford, J. R., Kellie, S. J., McCowage, G., Cohn, R., Fisher, M. J., Krasin, M. J., Stewart, C. F., Broniscer, A., Buchhalter, I., Tatevossian, R. G., Orr, B. A., Neale, G., Klimo, P., Boop, F., Srinivasan, A., Pfister, S. M., Gilbertson, R. J., Onar-Thomas, A., Ellison, D. W., & Northcott, P. A.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Baylor College of Medicine (US)
- Mayo Clinic (US)
- Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON
- University of Toronto (CA)
- The University of Queensland (AU)
- UF Health Shands Hospital (US)
- Duke University (US)
- Royal Children's Hospital (AU)
- The University of Melbourne (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Children's Hospital of Philadelphia (US)
- University of Pittsburgh (US)
- German Cancer Research Center (DE)
- Hartwell Center, St Jude Children's Research Hospital, Memphis, TN
- University of Tennessee Health Science Center (US)
- Cancer Research UK (GB)
- Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN
- ORCID
- Gajjar, Amar
- Robinson, Giles W.
- Smith, Kyle S.
- Lin, Tong
- Merchant, Thomas E.
- Chintagumpala, Murali
- Mahajan, Anita
- Su, Jack
- Bouffet, Eric
- Bartels, Ute
- Schechter, Tal
- Hassall, Tim
- Robertson, Thomas
- Nicholls, Wayne
- Gururangan, Sridharan
- Schroeder, Kristin
- Sullivan, Michael
- Hansford, Jordan R.
- McCowage, Geoffrey
- Cohn, Richard
- Fisher, Michael J.
- Krasin, Matthew J.
- Stewart, Clinton F.
- Broniscer, Alberto
- Buchhalter, Ivo
- Tatevossian, Ruth G.
- Orr, Brent A.
- Neale, Geoff
- Klimo, Paul
- Boop, Frederick
- Srinivasan, Ashok
- Pfister, Stefan M.
- Gilbertson, Richard J.
- Ellison, David W.
- Northcott, Paul A.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-03-01
- Volume
- 39
- Issue
- 7
- Pages
- 822-835
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10166353
- OpenAlex
- W3118854714
- Cited by
- 241
- References
- 28
- Citations by year
- 2026: 33 · 2025: 63 · 2024: 38 · 2023: 52 · 2022: 33 · 2021: 21
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- AstraZeneca
- Cancer Research UK (26398)
- Brain Tumour Charity (GN-000575)
- Genentech
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- medulloblastoma, risk-adapted treatment, molecular classification, Group 3 medulloblastoma, Group 4 medulloblastoma, DNA methylation profiling, CTNNB1 mutation, PTCH1 mutation, TP53 mutation, SMARCA4 mutation, progression-free survival, pediatric brain tumors
- MeSH terms
- Progression-Free Survival, Epigenome, Adolescent, Cerebellar Neoplasms, Child, Child, Preschool, DNA Mutational Analysis, Female, Humans, Magnetic Resonance Imaging, Male, Medulloblastoma, Mutation, Predictive Value of Tests, Risk Factors, Time Factors, Biomarkers, Tumor, Risk Assessment, DNA Methylation, Young Adult, Epigenomics, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
